Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

98.05 -1.47 (-1.48%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,289,768
Open 98.83
Bid (Size) 98.25 (1)
Ask (Size) 99.79 (1)
Prev. Close 99.52
Today's Range 97.90 - 99.68
52wk Range 94.48 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Is Merck the Next Big Weight-Loss Stock?
Via The Motley Fool

Performance

YTD
-13.41%
-13.41%
1 Month
-1.81%
-1.81%
3 Month
-15.20%
-15.20%
6 Month
-26.26%
-26.26%
1 Year
-8.96%
-8.96%

More News

Read More
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
Via The Motley Fool
Uncovering Dividend Opportunities with NYSE:MRK.
Via Chartmill
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued?
Via Talk Markets
Topics Stocks / Equities
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
From Merck & Co., Inc.
Via Business Wire
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Via Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
Stock Of The Day: Where Does The Merck Downtrend End?
Via Benzinga
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
What's Going On With Viking Therapeutics Stock On Wednesday?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
What's Going On With Merck Shares Wednesday?
Via Benzinga
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
From Merck & Co., Inc.
Via Business Wire
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Via Benzinga
Exposures Product Safety
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
Via Investor's Business Daily
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc. Merck
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.